Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors

Development of a cost effective and robust AlphaScreen® platform for application

(2018) John R Veloria et al.   BIOTECHNIQUES

Investigating the behavior of published PAINS alerts using a pharmaceutical company dataset

(2018) Lewis R. Vidler et al.   ACS Medicinal Chemistry Letters

CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin’s Lymphoma

(2018) Ranjana Advani et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Ecstasy and Agony of Assay Interference Compounds

(2017) Courtney Aldrich et al.   Journal of Chemical Information and Modeling

Comment on The Ecstasy and Agony of Assay Interference Compounds

(2017) Peter W. Kenny   Journal of Chemical Information and Modeling

Macrocycle peptides delineate locked-open inhibition mechanism for microorganism phosphoglycerate mutases

(2017) Hao Yu et al.   Nature Communications

Anti-leukemic activity and tolerability of anti-human CD47 monoclonal antibodies

(2017) E C Pietsch et al.   Blood Cancer Journal

Current approaches to increase CAR T cell potency in solid tumors: targeting the tumor microenvironment

(2017) Irene Scarfò et al.   Journal for ImmunoTherapy of Cancer

Protein–Protein Interaction Inhibition (2P2I)-Oriented Chemical Library Accelerates Hit Discovery

(2016) Sabine Milhas et al.   ACS Chemical Biology

Nivolumab Monotherapy for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer

(2016) Scott Gettinger et al.   JOURNAL OF CLINICAL ONCOLOGY

Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck

(2016) Robert L. Ferris et al.   NEW ENGLAND JOURNAL OF MEDICINE

Identification of tumorigenic cells and therapeutic targets in pancreatic neuroendocrine tumors

(2016) Geoffrey Wayne Krampitz et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Durable antitumor responses to CD47 blockade require adaptive immune stimulation

(2016) Jonathan T. Sockolosky et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Identification of pyrazolopyridazinones as PDEδ inhibitors

(2016) Björn Papke et al.   Nature Communications

Anti-CD47 Treatment Stimulates Phagocytosis of Glioblastoma by M1 and M2 Polarized Macrophages and Promotes M1 Polarized Macrophages In Vivo

(2016) Michael Zhang et al.   PLoS One

The Evolution of T-cell Therapies for Solid Malignancies

(2015) K. Fousek et al.   CLINICAL CANCER RESEARCH

Nuclear factor kappa B-mediated CD47 up-regulation promotes sorafenib resistance and its blockade synergizes the effect of sorafenib in hepatocellular carcinoma in mice

(2015) Jessica Lo et al.   HEPATOLOGY

CD47 Receptor Globally Regulates Metabolic Pathways That Control Resistance to Ionizing Radiation

(2015) Thomas W. Miller et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

CD47 blockade triggers T cell–mediated destruction of immunogenic tumors

(2015) Xiaojuan Liu et al.   NATURE MEDICINE

HIF-1 regulates CD47 expression in breast cancer cells to promote evasion of phagocytosis and maintenance of cancer stem cells

(2015) Huimin Zhang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

CD47 is an adverse prognostic factor and a therapeutic target in gastric cancer

(2015) Kazumichi Yoshida et al.   Cancer Medicine

Pre-Clinical Development of a Humanized Anti-CD47 Antibody with Anti-Cancer Therapeutic Potential

(2015) Jie Liu et al.   PLoS One

Co-expression of MET and CD47 is a novel prognosticator for survival of luminal-type breast cancer patients

(2015) Irène Baccelli et al.   Oncotarget

CD47 in the Tumor Microenvironment Limits Cooperation between Antitumor T-cell Immunity and Radiotherapy

(2014) D. R. Soto-Pantoja et al.   CANCER RESEARCH

Immune Escape and Survival Mechanisms in Circulating Tumor Cells of Colorectal Cancer

(2014) Gunnar Steinert et al.   CANCER RESEARCH

Protein–protein interaction modulator drug discovery: past efforts and future opportunities using a rich source of low- and high-throughput screening assays

(2014) Sheraz Gul et al.   Expert Opinion on Drug Discovery

Signal-regulatory proteinαfrom the NOD mouse binds human CD47 with an exceptionally high affinity - implications for engraftment of human cells

(2014) Lai Shan Kwong et al.   IMMUNOLOGY

Chemistry: Chemical con artists foil drug discovery

(2014) Jonathan Baell et al.   NATURE

Endoscopic molecular imaging of human bladder cancer using a CD47 antibody

(2014) Y. Pan et al.   Science Translational Medicine

The Interaction Between Signal Regulatory Protein Alpha (SIRPα) and CD47: Structure, Function, and Therapeutic Target

(2013) A. Neil Barclay et al.   Annual Review of Immunology

A Time-Resolved Fluorescence Resonance Energy Transfer Assay for High-Throughput Screening of 14-3-3 Protein–Protein Interaction Inhibitors

(2013) Yuhong Du et al.   ASSAY AND DRUG DEVELOPMENT TECHNOLOGIES

Cytokine patterns in patients with cancer: a systematic review

(2013) Bodo E Lippitz   LANCET ONCOLOGY

Thrombospondin-1 is a CD47-dependent endogenous inhibitor of hydrogen sulfide signaling in T cell activation

(2013) Thomas W. Miller et al.   MATRIX BIOLOGY

Anti-CD47 antibody-mediated phagocytosis of cancer by macrophages primes an effective antitumor T-cell response

(2013) D. Tseng et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Engineered SIRP  Variants as Immunotherapeutic Adjuvants to Anticancer Antibodies

(2013) K. Weiskopf et al.   SCIENCE

Minimal "Self" Peptides That Inhibit Phagocytic Clearance and Enhance Delivery of Nanoparticles

(2013) P. L. Rodriguez et al.   SCIENCE

CD47 deficiency confers cell and tissue radioprotection by activation of autophagy

(2012) David R. Soto-Pantoja et al.   Autophagy

Engulfment of hematopoietic stem cells caused by down-regulation of CD47 is critical in the pathogenesis of hemophagocytic lymphohistiocytosis

(2012) T. Kuriyama et al.   BLOOD

2P2Idb: a structural database dedicated to orthosteric modulation of protein–protein interactions

(2012) Marie Jeanne Basse et al.   NUCLEIC ACIDS RESEARCH

CD47 expression regulated by the miR-133a tumor suppressor is a novel prognostic marker in esophageal squamous cell carcinoma

(2012) SHIGEMASA SUZUKI et al.   ONCOLOGY REPORTS

CD47Low Status on CD4 Effectors Is Necessary for the Contraction/Resolution of the Immune Response in Humans and Mice

(2012) Vu Quang Van et al.   PLoS One

Antibody therapy targeting the CD47 protein is effective in a model of aggressive metastatic leiomyosarcoma

(2012) B. Edris et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors

(2012) S. B. Willingham et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

An Immunosurveillance Mechanism Controls Cancer Cell Ploidy

(2012) L. Senovilla et al.   SCIENCE

Heparan Sulfate Modification of the Transmembrane Receptor CD47 Is Necessary for Inhibition of T Cell Receptor Signaling by Thrombospondin-1

(2011) Sukhbir Kaur et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma

(2011) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

CD47-signal regulatory protein-  (SIRP ) interactions form a barrier for antibody-mediated tumor cell destruction

(2011) X. W. Zhao et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Apparent activity in high-throughput screening: origins of compound-dependent assay interference

(2010) Natasha Thorne et al.   CURRENT OPINION IN CHEMICAL BIOLOGY

New Substructure Filters for Removal of Pan Assay Interference Compounds (PAINS) from Screening Libraries and for Their Exclusion in Bioassays

(2010) Jonathan B. Baell et al.   JOURNAL OF MEDICINAL CHEMISTRY

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Atomic Analysis of Protein-Protein Interfaces with Known Inhibitors: The 2P2I Database

(2010) Raphaël Bourgeas et al.   PLoS One

Identification of Pregnane X Receptor Ligands Using Time-Resolved Fluorescence Resonance Energy Transfer and Quantitative High-Throughput Screening

(2009) Sunita J. Shukla et al.   ASSAY AND DRUG DEVELOPMENT TECHNOLOGIES

CD47 Is Upregulated on Circulating Hematopoietic Stem Cells and Leukemia Cells to Avoid Phagocytosis

(2009) Siddhartha Jaiswal et al.   CELL

CD47 Is an Adverse Prognostic Factor and Therapeutic Antibody Target on Human Acute Myeloid Leukemia Stem Cells

(2009) Ravindra Majeti et al.   CELL

Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum

(2009) Jing Yuan et al.   Nature Chemical Biology

Radioprotection in Normal Tissue and Delayed Tumor Growth by Blockade of CD47 Signaling

(2009) J. B. Maxhimer et al.   Science Translational Medicine

Differential Interactions of Thrombospondin-1, -2, and -4 with CD47 and Effects on cGMP Signaling and Ischemic Injury Responses

(2008) Jeff S. Isenberg et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Comprehensive Mechanistic Analysis of Hits from High-Throughput and Docking Screens against β-Lactamase

(2008) Kerim Babaoglu et al.   JOURNAL OF MEDICINAL CHEMISTRY

Paired Receptor Specificity Explained by Structures of Signal Regulatory Proteins Alone and Complexed with CD47

(2008) Deborah Hatherley et al.   MOLECULAR CELL